CatalystFDA/Bio

MIRUM FALLS DESPITE MEETING PRIMARY GOAL IN PHASE 3 BRELOVITUG STUDY FOR HEPATITIS D - SEEKINGALPHA

Mirum falls despite meeting primary goal in Phase 3 brelovitug study for hepatitis D.

What changed

Mirum falls despite meeting primary goal in Phase 3 brelovitug study for hepatitis D.

Why it matters

Mirum falls despite meeting primary goal in Phase 3 brelovitug study for hepatitis D. — impact context not separately stored; see What changed.

Sources